Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk
- PMID: 23291271
- PMCID: PMC3616673
- DOI: 10.1093/carcin/bgs407
Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk
Abstract
Genome-wide association studies (GWASs) have mainly focused on top significant single nucleotide polymorphisms (SNPs), most of which did not have clear biological functions but were just surrogates for unknown causal variants. Studying SNPs with modest association and putative functions in biologically plausible pathways has become one complementary approach to GWASs. To unravel the key roles of mitogen-activated protein kinase (MAPK) pathways in cutaneous melanoma (CM) risk, we re-evaluated the associations between 47 818 SNPs in 280 MAPK genes and CM risk using our published GWAS dataset with 1804 CM cases and 1026 controls. We initially found 105 SNPs with P ≤ 0.001, more than expected by chance, 26 of which were predicted to be putatively functional SNPs. The risk associations with 16 SNPs around DUSP14 (rs1051849) and a previous reported melanoma locus MAFF/PLA2G6 (proxy SNP rs4608623) were replicated in the GenoMEL dataset (P < 0.01) but failed in the Australian dataset. Meta-analysis showed that rs1051849 in the 3' untranslated regions of DUSP14 was associated with a reduced risk of melanoma (odds ratio = 0.89, 95% confidence interval: 0.82-0.96, P = 0.003, false discovery rate = 0.056). Further genotype-phenotype correlation analysis using the 90 HapMap lymphoblastoid cell lines from Caucasians showed significant correlations between two SNPs (rs1051849 and rs4608623) and messenger RNA expression levels of DUSP14 and MAFF (P = 0.025 and P = 0.010, respectively). Gene-based tests also revealed significant SNPs were over-represented in MAFF, PLA2G6, DUSP14 and other 16 genes. Our results suggest that functional SNPs in MAPK pathways may contribute to CM risk. Further studies are warranted to validate our findings.
Figures
References
-
- Howlader N, et al. SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011
-
- Hayward N.K. (2003). Genetics of melanoma predisposition. Oncogene, 22, 3053–3062 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA131274/CA/NCI NIH HHS/United States
- C8216/A6129/CRUK_/Cancer Research UK/United Kingdom
- R01 CA088363/CA/NCI NIH HHS/United States
- U01 CA049449/CA/NCI NIH HHS/United States
- R01ES011740/ES/NIEHS NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- R01 CA133996/CA/NCI NIH HHS/United States
- R01 CA083115/CA/NCI NIH HHS/United States
- R01CA131274/CA/NCI NIH HHS/United States
- CA100264/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- WT084766/Z/08/Z/WT_/Wellcome Trust/United Kingdom
- CA87969/CA/NCI NIH HHS/United States
- R01 ES011740/ES/NIEHS NIH HHS/United States
- CA49449/CA/NCI NIH HHS/United States
- CA88363/CA/NCI NIH HHS/United States
- HHSN268200782096C/HG/NHGRI NIH HHS/United States
- CA83115/CA/NCI NIH HHS/United States
- R01 CA122838/CA/NCI NIH HHS/United States
- CA133996/CA/NCI NIH HHS/United States
- C588/A10589/CRUK_/Cancer Research UK/United Kingdom
- R01 CA049449/CA/NCI NIH HHS/United States
- CA055075/CA/NCI NIH HHS/United States
- C588/A4994/CRUK_/Cancer Research UK/United Kingdom
- P50 CA093459/CA/NCI NIH HHS/United States
- 10589/CRUK_/Cancer Research UK/United Kingdom
- R01 CA100264/CA/NCI NIH HHS/United States
- CA122838/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
